Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-731-8180
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees117
Next Earnings Date10/22/2019 (Estimated)
OptionableNot Optionable
Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions
What is Odonate Therapeutics' stock symbol?
Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."
How were Odonate Therapeutics' earnings last quarter?
Odonate Therapeutics Inc (NASDAQ:ODT) released its quarterly earnings results on Wednesday, July, 24th. The company reported ($1.15) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.24) by $0.09. View Odonate Therapeutics' Earnings History.
When is Odonate Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Odonate Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Odonate Therapeutics.
Has Odonate Therapeutics been receiving favorable news coverage?
Headlines about ODT stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Odonate Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Odonate Therapeutics.
Are investors shorting Odonate Therapeutics?
Odonate Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,430,000 shares, an increase of 11.7% from the August 30th total of 1,280,000 shares. Based on an average daily trading volume, of 117,300 shares, the days-to-cover ratio is presently 12.2 days. Currently, 4.9% of the company's stock are short sold. View Odonate Therapeutics' Current Options Chain.
Who are some of Odonate Therapeutics' key competitors?
Some companies that are related to Odonate Therapeutics include United Therapeutics (UTHR), Arrowhead Pharmaceuticals (ARWR), FibroGen (FGEN), Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Myokardia (MYOK), Genmab A/S (GMAB), HUTCHISON CHINA/S (HCM) and Ultragenyx Pharmaceutical (RARE).
What other stocks do shareholders of Odonate Therapeutics own?
Who are Odonate Therapeutics' key executives?
Odonate Therapeutics' management team includes the folowing people:
- Mr. Kevin C. Tang, Chairman & CEO (Age 52)
- Mr. John G. Lemkey, Chief Operating Officer (Age 38)
- Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
- Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
- Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)
When did Odonate Therapeutics IPO?
(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.
Who are Odonate Therapeutics' major shareholders?
Odonate Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Strs Ohio (0.07%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.
Which institutional investors are buying Odonate Therapeutics stock?
ODT stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.
How do I buy shares of Odonate Therapeutics?
Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Odonate Therapeutics' stock price today?
One share of ODT stock can currently be purchased for approximately $28.08.
How big of a company is Odonate Therapeutics?
Odonate Therapeutics has a market capitalization of $903.81 million. The company earns $-88,960,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.View Additional Information About Odonate Therapeutics.
What is Odonate Therapeutics' official website?
How can I contact Odonate Therapeutics?
Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]
MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
